Clinical effect of double plasma molecular adsorption system in treatment of patients with chronic liver failure in high-altitude areas
Objective To investigate the differences in clinical features and mortality rate between native patients with chronic liver failure(CHF)and migrated patients with CHF after treatment with double plasma molecular adsorption system(DPMAS)in high-altitude areas.Methods A total of 63 patients with CHF who received DPMAS treatment in the intensive care unit of General Hospital of Tibet Military Command from January 2016 to December 2021 were enrolled,and according to their history of residence in high-altitude areas,they were divided into native group with 29 patients and migrated group with 34 patients.The two groups were compared in terms of baseline data and clinical features before and after DPMAS treatment.The independent-samples t test was used for comparison of normally distributed continuous data between groups,and the paired t-test was used for comparison before and after treatment within each group;the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups,and the Wilcoxon signed rank sum test was used for comparison before and after treatment within each group;the chi-square test was used for comparison of categorical data between groups.The Kaplan-Meier method was used to plot survival curves,and the Log-rank test was used for comparison of the risk of death.Results Compared with the native group,the migrated group had a significantly higher proportion of Chinese Han patients(χ2=41.729,P<0.001),and compared with the migrated group,the native group had a significantly longer duration of the most recent continuous residence in high-altitude areas(Z=3.364,P<0.001).Compared with the native group,the migrated group had significantly higher MELD score and incidence rates of hepatic encephalopathy,hepatorenal syndrome,and gastrointestinal bleeding(Z=2.318,χ2=6.903,5.154,and 6.262,all P<0.05).Both groups had significant changes in platelet count(PLT),hemoglobin count(HGB),alanine aminotransferase(ALT),aspartate aminotransferase(AST),albumin,total bilirubin(TBil),direct bilirubin(DBil),lactate dehydrogenase(LDH),creatinine(Cr),and international normalized ratio(INR)after DPMAS treatment(all P<0.05).Before DPMAS treatment,compared with the native group,the migrated group had significantly higher levels of ALT,AST,TBil,DBil,LDH,Cr,BUN,and INR(all P<0.05)and a significantly lower level of HGB(P<0.05);after DPMAS treatment,compared with the native group,the migrated group had significantly greater reductions in PLT and HGB(both P<0.05)and still significantly higher levels of ALT,AST,TBil,DBil,LDH,BUN,and INR(all P<0.05).The 60-day mortality rate of patients after DPMAS treatment was 52.5%(95%confidence interval[CI]:41.7—63.8)in the native group and 81.3%(95%CI:77.9—85.6)in the migrated group.Compared with the native group(hazard ratio[HR]=0.47,95%CI:0.23—0.95),the migrated group had a significant increase in the risk of death on day 60(HR=2.14,95%CI:1.06—4.32,P=0.039).Conclusion Compared with the native patients with CHF in high-altitude areas,migrated patients have a higher degree of liver impairment,a lower degree of improvement in liver function after DPMAS treatment,and a higher mortality rate.Clinical medical staff need to pay more attention to migrated patients with CHF,so as to improve their survival rates.
国家科技期刊平台
NSTL
万方数据
维普
